Healthcare Technologies extends loan maturity to April 2026

Healthcare Technologies Inc. entered a new Memorandum of Understanding with Kufu Company Holdings Inc. on March 31, 2026 to adjust an existing financing arrangement.

Accepted by SEC EDGAR 04/08/2026 - 06:34 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Healthcare Technologies Inc. entered a new Memorandum of Understanding with Kufu Company Holdings Inc. on March 31, 2026 to adjust an existing financing arrangement. The parties agreed to extend the maturity date of their previously disclosed Deemed Loan Agreement from March 31, 2026 to April 30, 2026, giving the Company an extra month before repaying principal under that loan. All interest that had accrued through March 31, 2026 under the Loan Agreement became due and payable when this new memorandum was executed, while all other loan terms remain unchanged. The company is also incorporating this report, including the exhibit containing the memorandum, by reference into its existing registration statements on Form S-8 and Form F-3.

Key Terms

Memorandum of Understanding, Deemed Loan Agreement, registration statements on Form S-8, Form F-3, +1 more

5 terms

Memorandum of Understanding financial

"entered into a Memorandum of Understanding (the " Memorandum of Understanding ")"

A memorandum of understanding (MOU) is a formal agreement between two or more parties that outlines their shared intentions and plans to work together. It acts like a handshake in writing, clarifying each side’s roles and expectations before any official contract is signed. For investors, an MOU signals that parties are serious about collaboration, which can influence future business opportunities and potential growth.

Deemed Loan Agreement financial

"extend the maturity date of the previously disclosed Deemed Loan Agreement"

registration statements on Form S-8 regulatory

"into and as part of the Company’s registration statements on Form S-8"

Form F-3 regulatory

"and Form F-3 (Registration Number 333-290161)"

Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.

foreign private issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Healthcare Technologies Inc. (MRM) change in its loan agreement?

Healthcare Technologies Inc. and Kufu Company Holdings Inc. extended the maturity date of their existing Deemed Loan Agreement from March 31, 2026 to April 30, 2026, while keeping all other loan terms in place.

When is the new loan maturity date for Healthcare Technologies Inc. (MRM)?

The new maturity date for the Deemed Loan Agreement is April 30, 2026. Previously, the loan was scheduled to mature on March 31, 2026, so the change effectively grants a one-month extension.

What happened to accrued interest under Healthcare Technologies Inc.’s (MRM) Loan Agreement?

All interest that had accrued under the Loan Agreement through March 31, 2026 became due and payable upon execution of the March 31, 2026 Memorandum of Understanding between Healthcare Technologies Inc. and the bond holder.

Did Healthcare Technologies Inc. (MRM) change other terms of its Loan Agreement?

No, other than extending the maturity date and requiring accrued interest payment through March 31, 2026, all other terms of the existing Loan Agreement remain in full force and effect according to the filing.

How is this Form 6-K used in Healthcare Technologies Inc. (MRM) registration statements?

Healthcare Technologies Inc. is incorporating this Form 6-K, including its exhibit, by reference into its registration statements on Form S-8 and Form F-3, making the disclosed information part of those offerings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April, 2026

Commission File Number 001-39809

MEDIROM HEALTHCARE TECHNOLOGIES INC.

(Translation of registrant’s name into English)

2-3-1 Daiba, Minato-ku

Tokyo 135-0091, Japan

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

x Form 20-F ¨ Form 40-F

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

Memorandum of Understanding

On March 31, 2026, MEDIROM Healthcare Technologies Inc. (the “Company”) and Kufu Company Holdings Inc. (the “Bond Holder”) entered into a Memorandum of Understanding (the " Memorandum of Understanding "), pursuant to which the parties agreed to extend the maturity date of the previously disclosed Deemed Loan Agreement and a Memorandum of Understanding, each dated January 30, 2026 (collectively, the "Loan Agreement"), between the Company and the Bond Holder, from March 31, 2026 to April 30, 2026. All interest accrued through March 31, 2026 under the Loan Agreement also became due and payable upon execution of the Memorandum of Understanding. All other terms of the Loan Agreement remain in full force and effect.

The foregoing description of the Memorandum of Understanding does not purport to be complete and is qualified in its entirety by reference to the full text of the Memorandum of Understanding, which is furnished herewith as Exhibit 10.1 hereto and incorporated herein by reference.

The information furnished in this report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, as amended, except to the extent specifically provided in such a filing. The registrant hereby incorporates this report on Form 6-K (including the exhibit hereto) by reference into and as part of the Company’s registration statements on Form S-8 (Registration No. 333-274833) and Form F-3 (Registration Number 333-290161), and this report on Form 6-K shall be deemed to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished (to the extent the Company expressly states that it incorporates such furnished information by reference into such registration statement) by the Company.

EXHIBIT INDEX

Exhibit No.		Description
10.1		Memorandum of Understanding, dated March 31, 2026, by and between the Company and the Bond Holder [English Translation]

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	MEDIROM HEALTHCARE TECHNOLOGIES INC.
Date: April 8, 2026
	By:	/s/ Fumitoshi Fujiwara
		Name: Fumitoshi Fujiwara
		Title: Chief Financial Officer

Filing Exhibits & Attachments

1 document

Agreements & Contracts

• EX-10.1 EXHIBIT 10.1 6.9 KB